Ethical considerations concerning treatment allocation in drug development trials
From MaRDI portal
Publication:5424156
DOI10.1191/0962280202sm299razbMath1121.62661OpenAlexW2062336256WikidataQ30332007 ScholiaQ30332007MaRDI QIDQ5424156
No author found.
Publication date: 2 November 2007
Published in: Statistical Methods in Medical Research (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1191/0962280202sm299ra
Related Items
Notes on testing equality in binary data under a three period crossover design, Test and estimation in binary data analysis under an incomplete block crossover design, Maximin efficiencies under treatment-dependent costs and outcome variances for parallel, AA/BB, and AB/BA designs, The finite sample performance of the two-stage analysis of a two-period crossover trial, Bayesian crossover designs for generalized linear models, Notes on power comparison between the sequential parallel comparison and other commonly-used designs, Notes on the two-stage procedure under an incomplete block two-period crossover design, Notes on misspecifying the random effects distribution regarding analysis under the AB/BA crossover trial in dichotomous data – a Monte Carlo evaluation, Robustness and monotonicity properties of generalized correlation coefficients, A Bayesian analysis of the incomplete block crossover design, Estimation of the proportion ratio under a simple crossover trial, Notes on estimation in Poisson frequency data under an incomplete block crossover design, A review of uniform cross-over designs, On wide sense stationary processes over finite non-abelian groups, Nonparametric approaches to the analysis of crossover studies, Group sequential crossover trial designs with strong control of the familywise error rate, On uniformly balanced crossover designs efficient under subject dropout
Cites Work
